212 related articles for article (PubMed ID: 27040278)
1. Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles.
Reboursiere E; Fouques H; Maigne G; Johnson H; Chantepie S; Gac AC; Reman O; Macro M; Benabed K; Troussard X; Damaj G; Cheze S
Int J Hematol; 2016 Jul; 104(1):85-91. PubMed ID: 27040278
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
[TBL] [Abstract][Full Text] [Related]
3. Reemergence of Splenectomy for ITP Second-line Treatment?
Chater C; Terriou L; Duhamel A; Launay D; Chambon JP; Pruvot FR; Rogosnitzky M; Zerbib P
Ann Surg; 2016 Nov; 264(5):772-777. PubMed ID: 27741009
[TBL] [Abstract][Full Text] [Related]
4. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
[TBL] [Abstract][Full Text] [Related]
5. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.
Al Askar AS; Shaheen NA; Al Zahrani M; Al Otaibi MG; Al Qahtani BS; Ahmed F; Al Zughaibi M; Kamran I; Mendoza MA; Khan A
Int J Hematol; 2018 Jan; 107(1):69-74. PubMed ID: 28895035
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
[TBL] [Abstract][Full Text] [Related]
7. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
8. Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment.
Chang H; Tang TC; Hung YS; Li PL; Kuo MC; Wu JH; Wang PN
Eur J Haematol; 2018 Oct; 101(4):549-555. PubMed ID: 30007087
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura.
Pasa S; Altintas A; Cil T; Danis R; Ayyildiz O
J Thromb Thrombolysis; 2009 Apr; 27(3):329-33. PubMed ID: 18311541
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura.
Vancine-Califani SM; De Paula EV; Ozelo MC; Orsi FL; Fabri DR; Annichino-Bizzacchi JM
Platelets; 2008 Nov; 19(7):489-95. PubMed ID: 18979360
[TBL] [Abstract][Full Text] [Related]
12. Response to splenectomy is durable after a certain point in time in adult patients with chronic immune thrombocytopenic purpura.
Johansson E; Engervall P; Landgren O; Grimfors G; Widell S; Rezai S; Björkholm M
Eur J Haematol; 2006 Jul; 77(1):61-6. PubMed ID: 16573739
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
[TBL] [Abstract][Full Text] [Related]
14. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
[TBL] [Abstract][Full Text] [Related]
15. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
Zaja F; Marin L; Chiozzotto M; Puglisi S; Volpetti S; Fanin R
Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux.
Deshayes S; Khellaf M; Zarour A; Layese R; Fain O; Terriou L; Viallard JF; Cheze S; Graveleau J; Slama B; Audia S; Cliquennois M; Ebbo M; Le Guenno G; Salles G; Bonmati C; Teillet F; Galicier L; Lambotte O; Hot A; Lefrère F; Mahévas M; Canoui-Poitrine F; Michel M; Godeau B
Am J Hematol; 2019 Dec; 94(12):1314-1324. PubMed ID: 31489694
[TBL] [Abstract][Full Text] [Related]
17. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.
Godeau B; Porcher R; Fain O; Lefrère F; Fenaux P; Cheze S; Vekhoff A; Chauveheid MP; Stirnemann J; Galicier L; Bourgeois E; Haiat S; Varet B; Leporrier M; Papo T; Khellaf M; Michel M; Bierling P
Blood; 2008 Aug; 112(4):999-1004. PubMed ID: 18463354
[TBL] [Abstract][Full Text] [Related]
18. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity.
Moulis G; Sailler L; Sommet A; Lapeyre-Mestre M; Derumeaux H; Adoue D
Am J Hematol; 2014 Jan; 89(1):41-6. PubMed ID: 24038066
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study.
Park YH; Yi HG; Lee MH; Kim CS; Lim JH
Int J Hematol; 2016 Feb; 103(2):180-8. PubMed ID: 26588926
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients.
Aleem A; Alaskar AS; Algahtani F; Rather M; Almahayni MH; Al-Momen A
Int J Hematol; 2010 Sep; 92(2):283-8. PubMed ID: 20640541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
